Marc Overhage, MD, PhD
Chief Medical Informatics Officer
Siemens Health Services
Prior to joining Siemens where he leads product strategy and research, Dr. Overhage was the founding Chief Executive Officer of the Indiana Health Information Exchange and was Director of Medical Informatics at the Regenstrief Institute, Inc., and a Sam Regenstrief Professor of Medical Informatics at the Indiana University School of Medicine. He has spent over 25 years developing and implementing scientific and clinical systems and evaluating their value. With his colleagues from the Regenstrief Institute, he created a community wide electronic medical record (Indiana Network for Patient Care) containing data from many sources including laboratories, pharmacies, physician practices and hospitals in central Indiana. In order to create a sustainable financial model, he helped create the Indiana Health Information Exchange, a not-for-profit corporation. He has developed and evaluated clinical decision support including inpatient and outpatient computerized physician order entry and the underlying knowledge bases to support them.
Over the last decade, Dr. Overhage has played a significant regional and national leadership role in advancing the policy, standards, financing and implementation of health information exchange. He serves on the Health Information Technology Standards Committee and the Board of Directors of the National Quality Form as well as being engaged in a number of national healthcare initiatives. He is a member of the Institute of Medicine, a fellow of the American College of Medical Informatics and the American College of Physicians. He received the Davies Recognition Award for Excellence in Computer-Based Patient Recognition for the Regenstrief Medical Record System. Dr. Overhage was a resident in internal medicine, a medical informatics and health services research fellow and then chief medical resident at the Indiana University School of Medicine. He practiced general internal medicine for over 20 years including the ambulatory, inpatient and emergency care settings.
Boyce RD, Ryan PB, Noren GN, et al. Bridging Islands of Information to Establish an Integrated Knowledge Base of Drugs and Health Outcomes of Interest. Drug Saf. 2014 Jul 2;2:2.
Madigan D, Stang PE, Berlin JA, et al. A Systematic Statistical Approach to Evaluating Evidence from Observational Studies. Annual Review of Statistics and Its Application. 2014;1(1):11-39.
Stang P, Ryan P, Hartzema AG, et al. Development and Evaluation of Infrastructure and Analytic Methods for Systematic Drug Safety Surveillance: Lessons and Resources from the Observational Medical Outcomes Partnership. In: Elizabeth B. Andrews NM, editor. Mann’s Pharmacovigilance. Third ed: Wiley-Blackwell; 2014. p. 866.
Ryan PB, Stang PE, Overhage JM, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013 Oct;36(Suppl 1):S143-58. doi: 10.1007/s40264-013-0108-9.
Hartzema AG, Reich CG, Ryan PB, et al. Managing data quality for a drug safety surveillance system. Drug Saf. 2013 Oct;36(Suppl 1):S49-58. doi: 10.1007/s40264-013-0098-7.
Stang PE, Ryan PB, Overhage JM, Schuemie MJ, Hartzema AG, Welebob E. Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey. Drug Saf. 2013 Oct;36(Suppl 1):S15-25. doi: 10.1007/s40264-013-0103-1.
Overhage JM, Ryan PB, Schuemie MJ, Stang PE. Desideratum for evidence based epidemiology. Drug Saf. 2013 Oct;36(Suppl 1):S5-14. doi: 0.1007/s40264-013-0102-2.
Madigan D, Ryan PB, Schuemie M, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013 Aug 15;178(4):645-51. doi: 10.1093/aje/kwt010. Epub 2013 May 5.
Ryan PB, Madigan D, Stang PE, Marc Overhage J, Racoosin JA, Hartzema AG. Response to comment on ’empirical assessment of methods for risk identification in healthcare data’. Stat Med. 2013 Mar 15;32(6):1075-7. doi: 10.02/sim.5725.
Overhage JM, Overhage LM. Sensible use of observational clinical data. Statistical Methods in Medical Research. 2013;22(1):7-13.
Li X, Hui S, Ryan P, Rosenman M, Overhage M. Statistical visualization for assessing performance of methods for safety surveillance using electronic databases. Pharmacoepidemiol Drug Saf. 2013 May;22(5):503-9. doi: 10.1002/pds.3419. Epub 2013 Feb 14.
Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012 Dec 30;31(30):4401-15. doi: 10.1002/sim.5620. Epub 2012 Sep 27.
Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012 Jan-Feb;19(1):54-60. doi: 10.1136/amiajnl-2011-000376. Epub 2011 Oct 28.
Stang PE, Ryan PB, Dusetzina SB, et al. Health Outcomes of Interest in Observational Data: Issues in Identifying Definitions in the Literature. Health Outcomes Research in Medicine. 2012 2//;3(1):e37-e44.
Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010 Nov 2;153(9):600-6. doi: 10.7326/0003-4819-153-9-201011020-00010.
Ryan P, Welebob E, Hartzema A, Stang P, Overhage JM. Surveying US Observational Data Sources and Characteristics for Drug Safety Needs. Pharm Med. 2010 2010/08/01;24(4):231-8.
